ATE81285T1 - Freisetzungssysteme fuer die kontrollierte anwendung von lhrh-analoga. - Google Patents

Freisetzungssysteme fuer die kontrollierte anwendung von lhrh-analoga.

Info

Publication number
ATE81285T1
ATE81285T1 AT88107345T AT88107345T ATE81285T1 AT E81285 T1 ATE81285 T1 AT E81285T1 AT 88107345 T AT88107345 T AT 88107345T AT 88107345 T AT88107345 T AT 88107345T AT E81285 T1 ATE81285 T1 AT E81285T1
Authority
AT
Austria
Prior art keywords
delivery systems
controlled use
lhrh analogues
controlled
lhrh analog
Prior art date
Application number
AT88107345T
Other languages
English (en)
Inventor
Lynda M Sanders
Ramon A Burns Jr
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Application granted granted Critical
Publication of ATE81285T1 publication Critical patent/ATE81285T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Reduction Or Emphasis Of Bandwidth Of Signals (AREA)
  • Materials For Medical Uses (AREA)
AT88107345T 1987-05-08 1988-05-06 Freisetzungssysteme fuer die kontrollierte anwendung von lhrh-analoga. ATE81285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/047,738 US5028430A (en) 1987-05-08 1987-05-08 Delivery systems for the controlled administration of LHRH analogs
EP88107345A EP0293632B1 (de) 1987-05-08 1988-05-06 Freisetzungssysteme für die kontrollierte Anwendung von LHRH-Analoga

Publications (1)

Publication Number Publication Date
ATE81285T1 true ATE81285T1 (de) 1992-10-15

Family

ID=21950670

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88107345T ATE81285T1 (de) 1987-05-08 1988-05-06 Freisetzungssysteme fuer die kontrollierte anwendung von lhrh-analoga.

Country Status (11)

Country Link
US (1) US5028430A (de)
EP (1) EP0293632B1 (de)
JP (1) JPH0686391B2 (de)
AT (1) ATE81285T1 (de)
AU (1) AU621294B2 (de)
CA (1) CA1336579C (de)
DE (1) DE3875160T2 (de)
ES (1) ES2052636T3 (de)
GR (1) GR3005901T3 (de)
IE (1) IE62969B1 (de)
NZ (1) NZ224520A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0657170A1 (de) * 1993-12-09 1995-06-14 ASTA Medica Aktiengesellschaft Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387419A (en) * 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
IL87982A0 (en) * 1988-10-10 1989-03-31 Israel Oceanographic & Limnolo Compositions and methods for manipulating ovulation and spawning in fish
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
ES2136624T3 (es) * 1991-10-21 1999-12-01 Peptech Limited Implante biocompatible para regular la ovulacion en yeguas.
ES2150427T3 (es) * 1992-06-02 2000-12-01 Bard Inc C R Procedimiento y dispositivo de implante para el suministro de farmacos a largo plazo.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5733565A (en) * 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6117441A (en) * 1998-07-02 2000-09-12 The Population Council, Inc. Silicone core long term androgen delivery implant
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
CN1438861A (zh) 2000-04-26 2003-08-27 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
US20040234572A1 (en) * 2001-09-11 2004-11-25 Martinod Serge R. Preparation of sustained release pharmaceutical composition
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
JP2008500973A (ja) * 2004-05-31 2008-01-17 スマート ドラッグ システムズ インコーポレイティド 持続放出組成物
US20120156049A1 (en) * 2005-12-14 2012-06-21 Hong Shek C Method and coating for protecting and repairing an airfoil surface
US20090162416A1 (en) * 2007-12-19 2009-06-25 Dunham Rex A Polymer implants for timed release of drugs with particular emphasis on ovulation or spermiation of fish
US20120163981A1 (en) * 2010-12-22 2012-06-28 Hong Shek C Method and coating for protecting and repairing an airfoil surface
CN111278902B (zh) * 2017-11-23 2022-01-04 丹麦科技大学 具有可控释放曲线的作为活性基体的甘油-有机硅弹性体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791632A (fr) * 1971-11-20 1973-05-21 Schering Ag Supports a base de caoutchouc siliconique pour agents medicamenteux
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
IT1149971B (it) * 1979-06-11 1986-12-10 Syntex Inc Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4581169A (en) * 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
JPS62174031A (ja) * 1985-10-11 1987-07-30 Sumitomo Pharmaceut Co Ltd 高分子量薬物含有徐放性製剤
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0657170A1 (de) * 1993-12-09 1995-06-14 ASTA Medica Aktiengesellschaft Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5663145A (en) * 1993-12-09 1997-09-02 Asta Medica Aktiengesellschaft Products for administering an initial high dose of Cetrorelix and producing a combination package for use when treating diseases

Also Published As

Publication number Publication date
EP0293632B1 (de) 1992-10-07
EP0293632A1 (de) 1988-12-07
CA1336579C (en) 1995-08-08
ES2052636T3 (es) 1994-07-16
DE3875160D1 (de) 1992-11-12
IE881365L (en) 1988-11-08
AU1568288A (en) 1988-11-10
JPH0686391B2 (ja) 1994-11-02
JPS6445318A (en) 1989-02-17
NZ224520A (en) 1990-12-21
GR3005901T3 (de) 1993-06-07
AU621294B2 (en) 1992-03-12
DE3875160T2 (de) 1993-03-18
US5028430A (en) 1991-07-02
IE62969B1 (en) 1995-03-08

Similar Documents

Publication Publication Date Title
ATE81285T1 (de) Freisetzungssysteme fuer die kontrollierte anwendung von lhrh-analoga.
ATE361093T1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
ATE208612T1 (de) Biologisch erodierbare vorrichtung zur verabreichung von wirkstoffen
ATA163188A (de) Septum fuer implantierbare vorrichtungen zur abgabe von wirkstoffen
GR3006220T3 (de)
EP0281236A3 (en) Pharmaceutical delivery device
NO872381D0 (no) Fremgangsmaate for fremstilling av langsomt frigivende preparater.
DE69637961D1 (de) Verabreichung von biologisch aktiven polypeptiden
ATE117548T1 (de) Pharmazeutische zubereitungen zur verhütung von arzneimitteltoleranz.
ATE58473T1 (de) Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.
OA09736A (en) "Human interleukin-3 and muteins thereof".
DE3769707D1 (de) Therapeutisches system mit geregelter wirkstoffabgabe.
KR890700375A (ko) 피부에 유효약제를 조절하여 투여하는 유효약제-함유 플래스터
EP0160501A3 (de) Intranasale Zusammenstellung mit verzögerter Freigabe und Gebrauchsanweisung
DE68928528D1 (de) Verwendung von GnRH, LHRH oder ihre Derivate enthaltende Zubereitungen mit verzögerter Wirkstofffreisetzung
EP0228448A4 (de) Verwendung biologisch aktiver Copolymere zur Herstellung eines Arzneimittels zur Stimulierung des Wachstums von Tieren.
CS9001136A2 (en) Method of transdermal therapeutical system's production with active substance's graded liberation and application for active substances' local or systemic administration
IE890908L (en) Reservoir for controlled delivery
FR2569987B1 (fr) Dispositif implantable autonome et son utilisation pour l'administration de substances actives dans le corps humain
EP0213552A3 (de) Ölige Suspensionen zur intrarektalen Infusion
DE69230063D1 (de) Elektrisches Gerät zur transdermalen Verabreichung von Medikamenten mit einem entgegenwirkenden Produkt
Stirn et al. Mithramycin induced lactic acidosis.
Malinowska et al. Effect of malathion on survival rate of human lymphocytes stimulated with phytohaemagglutinin.
ITTO920035V0 (it) Supporto per un iniettore di un'apparecchiatura di somministrazione diliquido nel corpo di un paziente

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time